Heng Lin

Research Assistant Professor

University of Michigan
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Supplemental Figure 6. (A, B) Tumor growth inhibition analysis for Figure 6A conducted on day 42 (A) and Figure 6C conducted on day 32 (B). Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. MTV ± SD are denoted for each treatment group along with the calculated TGI.

Year:

2025

PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)–mediated antitumoral immune responses. We hypothesized that the PARP inhibitor olaparib would also potentiate radiation-induced T1IFN to promote antitumor immune responses and sensitization of otherwise resistant PDAC to immunotherapy. To test this hypothesis, we assessed the effects of olaparib and radiation on T1IFN production and sensitivity to αPD-L1 immunotherapy, as well as on the tumor microenvironment by single-cell RNA sequencing. We found that olaparib enhanced T1IFN production after radiation and had superior therapeutic efficacy in immunocompetent models. Olaparib and radiation treatment sensitized PDAC tumors to αPD-L1, resulting in decreased tumor burden and a 33% complete response rate. Combination treatment provided durable immune responses as shown by tumor rejection upon tumor rechallenge of previously cured mice. Furthermore, single-cell RNA sequencing analysis revealed that combination treatment induced an immunogenic tumor microenvironment characterized by interferon (IFN) responses in both PDAC and myeloid cell populations, macrophage polarization, and increased CD8 + terminal effector T-cell frequency and activity, findings which were confirmed by IHC and flow cytometry. Furthermore, CD8 + T cells and T1IFN signaling were required for therapeutic efficacy as host depletion of CD8 + T cells or the T1IFN receptor diminished treatment responses. Overall, our results indicate that olaparib enhances radiation-induced T1IFN-mediated immune signaling and subsequently an adaptive immune response, thus sensitizing pancreatic cancer to αPD-L1 therapy, supporting an ongoing clinical trial of this therapy in patients with PDAC. See related commentary by Buchsbaum, p. 840

Year:

2025

Supplemental Figure 3. (A) UMAP projections of all cell clusters from harvested subcutaneous mT4 tumors following 5 days of treatment. Mice were treated with 1 dose (8 Gy) radiation on day 0, five doses olaparib (50 mg/kg) on days 0-4, and two doses of αPD-L1 (100 µg) on days -1, and 2. Tumors were harvested on day 4. (B) Dotplot showing an incomplete list of markers used to name cell clusters. The size of the circle represents the percentage of cells within that cluster that express the given gene. The color represents the average fold change expression of that gene within that cluster. (C) Gene signature analysis conducted on all cells for the listed immune signaling pathways. Enrichment module (EM) scores were calculated from gene signature scores using the following equation: (1/2 x Q2) + (1/4 x Q1) + (1/4 x Q3). EM scores for the indicated pathways were combined to create the resultant heatmap. (D, G) PDAC (D) and myeloid (G) cell clusters colored by corresponding treatment group (D) or by cell identity (G). (E) Gene signature analysis on PDAC cells for immune signaling pathways. Gene signature module scores were averaged and combined for each of the listed pathways to make the resultant heat map. (F, H) GSEAplots of important pathways which showed enrichment in PDAC cell comparisons (F) or myeloid cell comparisons (H) following GSEA. These include G2M checkpoint, interferon alpha response, interferon gamma response, and UV response down for the comparison between olaparib+radiation+αPD-L1 PDAC cells and radiation+αPD-L1 PDAC cells (F), interferon gamma response and interferon alpha response for the comparison between olaparib+radiation+αPD-L1 myeloid cells and control treatment myeloid cells, and TGFβ signaling and oxidative phosphorylation for the comparison between olaparib+radiation+αPD-L1 myeloid cells and radiation+αPD-L1 myeloid cells (H). (I) Violin plots displaying gene signature analysis conducted on macrophages for M2 macrophage phenotype and phagocytosis. Statistical significance was determined by Wilcoxon test. *P

Year:

2025

Supplemental Figure 4. (A-D) Workflow of CD8 + T cell isolation. All T cells (excluding cycling T cells) were isolated (A) and CD8 + , CD4 + , and NK status was determined (B). CD8 + T cells were further isolated and clustered (C). CD8 + only status was confirmed via violin plots of Cd8a, Cd4, and Fcer1g (D). (E) UMAP projection of CD8 + T cell clusters split by treatment group. (F) Bar plot displaying the percentage of total cells sequenced identified as B cells. (G) GSEAplots of important pathways found to be enriched in CD8 + T cell comparisons following GSEA including interferon alpha response, interferon gamma response, IL2/STAT5 signaling, and G2M checkpoint for the comparison between olaparib+radiation+αPD-L1 CD8 + T cells and radiation+αPD-L1 CD8 + T cells.

Year:

2025

Supplemental Figure 1. (A-S) Pancreatic cancer cells were treated with olaparib (5 µmol/L) one hour before radiation treatment (8 Gy) and collected 72 hours after treatment for analysis via flow cytometry, qRT-PCR or ELISA, unless otherwise denoted. (A) Panc-1 cells stably expressing IFNβ1 -promoter GFP-reporter were treated with radiation and/or talazoparib (10 nmol/L or 30 nmol/L). Analyzed via flow cytometry for mean fluorescence intensity (MFI) of GFP. Data are the mean of 3 independent experiments. (B) KPC2 cells were treated with olaparib (3µmol/L or 5µmol/L) and/or radiation (8 Gy) and collected at 24 hours, 48 hours, and 72 hours after radiation treatment. qRT-PCR was conducted for Ifnβ . Data are the mean fold change ± SEM relative to control treatment for each time point and represent 1 independent experiment performed in technical triplicate. (C) Panc-1 cells in which cGAS was knocked out using a CRISPR/Cas9 system were treated with olaparib and/or radiation and harvested for analysis via western blot for pTBK1, pSTAT1, STAT1 and Actin. (D-F) KPC2 cells were treated with olaparib (3µmol/L or 5µmol/L) and/or radiation (8 Gy) and collected at 24 hours, 48 hours, and 72 hours after radiation treatment. qRT-PCR was conducted for Cxcl9 (D), Cxcl10 (E), and Mx1 (F). Data are the mean fold change ± SEM relative to control treatment for each time point and represent 1 independent experiment performed in technical triplicate. (G-I) KPC2 cells were treated with olaparib (5µmol/L) one hour before various doses of radiation (2 Gy, 4 Gy, 6 Gy, 8 Gy, 10 Gy, 2 GyX3). Cells were collected 72 hours after treatment and RNA was extracted. qRT-PCR was conducted for Ifnβ (G), Cxcl9 (H), and Cxcl10 (I). Data are the mean fold change ± SEM relative to control treatment and represent 3 independent experiments performed in technical triplicate. (J, K) qRT-PCR targeting Mx1 in KPC2 (J) and mT4 (K) cells. Data are shown as mean fold change ± SEM relative to the control treatment and represent 4 (J) or 3 (K) independent experiments performed in technical triplicate. (L, M) Protein abundance quantification of CXCL9 (L) and CXCL10 (M) via ELISA in the media from KPC2 cells 72 hours after treatment with olaparib (3µmol/L or 5µmol/L) and/or radiation. Herring testis DNA (HS DNA) was transfected into cells (2µg) as a positive control. Data are average protein abundance ± SD. The graphs presented are representative of 2 independent experiments run in technical triplicate. (N) KPC2 cells treated in the absence or presence of IFNAR1 blocking antibody (5 µg/mL). Cells were collected 72 hours later and analyzed via flow cytometry for surface PD-L1 expression. Data are shown as MFI ± SEM relative to control treatment and represent 3 independent experiments performed in technical triplicate. (O-S) Flow cytometry analysis of PD-L1 (O, P) or MHC-I (Q-S) surface expression on MiaPaCa2 (O, R), AsPC-1 (P, S), and Panc-1 (Q). Data are shown as MFI ± SEM relative to control treatment and represent 1 (P, S), 2 (O, R) or 3 (Q) independent experiments performed in technical triplicate. Statistical significance was determined by a one-way ANOVA test (N) or a two-tailed, unpaired t test (A, G-I, J). *P

Year:

2025

Supplemental Figure 2. (A) Tumor growth inhibition analysis for Figure 2A conducted on day 13. Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. Mean tumor volume (MTV) ± standard deviation (SD) are denoted for each treatment group along with the calculated percent tumor growth inhibition (%TGI). (B) C57BL/6 mice with subcutaneous mT4 tumors were treated with αPD-L1 pre-, concurrent, or post-olaparib and radiation treatment. The different schedules are concurrent treatment with αPD-L1 (olaparib on days 1-5, and 8-12; radiation on day 1; αPD-L1 treatment on days 0 and 3), pre-treatment with αPD-L1 (olaparib on days 7-11 and 14-18; radiation on day 7; αPD-L1 treatment on days 0 and 3) and post-treatment with αPD-L1 (olaparib on days 0-4 and 7-11; radiation on day 0; αPD-L1 treatment on days 7 and 10). Data represent mean tumor volumes ± SEM from n= 10 (IgG), 20 (concurrent treatment), 20 (pre-treatment), and 20 (post-treatment) tumors per treatment group. (C) Serum was collected for each treatment condition on day 15 from 3 mice undergoing treatment in panel B. Complete blood cell count was conducted at the University of Michigan by the Unit for Laboratory Animal Medicine (RRID: SCR_025790) using a Heska HT5 Element. Percentage of white blood cells and lymphocytes from total serum are shown. (D) Tumor growth inhibition analysis for Figure 2B conducted on day 13. Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. MTV ± SD are denoted for each treatment group along with the calculated TGI. (E) Mouse weights monitored throughout treatment with olaparib, radiation, and αPD-L1. This data is from mice used Figure 2F. Data represent the average mouse weight (g) ± SEM from n= 6 (IgG), 7 (αPD-L1), 6 (olaparib+IgG), 7 (olaparib+αPD-L1), 8 (RT+IgG), 10 (RT+αPD-L1), 7 (olaparib+RT+IgG) and 9 (olaparib+RT+αPD-L1) mice per treatment group. (F) Individual tumor growth curves from mice used in Figure 2F. Data are represented as tumor volume and show n= 6 (IgG), 7 (αPD-L1), 6 (olaparib+IgG), 7 (olaparib+αPD-L1), 8 (RT+IgG), 10 (RT+αPD-L1), 7 (olaparib+RT+IgG), and 9 (olaparib+RT+αPD-L1) tumors per treatment group. (G, H) Tumor growth inhibition analysis for Figure 2D conducted on day 31 (G) and Figure 2F conducted on day 44 (H). Tumor growth inhibition was calculated [1-(average tumor volume of treated group/average tumor volume of control group)] x 100%. MTV ± SD are denoted for each treatment group along with the calculated TGI.

Year:

2025

Supplemental Figure 5. (A) C57BL/6 mice with subcutaneous mT4 tumors were treated as illustrated in Figure 2E tumors were harvested at day 4. Tumors were analyzed via flow cytometry for presence of Ki67 + . Data represent mean ± SEM (n=5 tumors per treatment group) and are represented as percentage from CD8a + cells.

Year:

2025

UBA1 inactivation upregulates interferon signaling via stabilization of JAK1. A, Hallmark pathways enriched by bulk RNA-seq of tumors with Uba1 depletion (sg Uba1 ) versus control from the B16-BL6 (left) or Myc-CaP (right) subcutaneous tumor models. B, Hallmark pathways enriched by bulk RNA-seq of tumors with Uba1 overexpression (OE) versus control (empty vector) from the Myc-CaP subcutaneous tumor model (left) or of Myc-CaP subcutaneous tumors in TAK-243–treated vs. control mice (right). C, Left: UMAP of pooled CD45 + and CD45 − cells from the indicated Myc-CaP tumors subjected to scRNA-seq. Clusters of malignant cells and leukocytes are shown. Right: hallmark pathways enriched by the scRNA-seq (shown in the left) of tumors with Uba1 depletion (sg Uba1 ) versus control or tumors in TAK-243–treated vs. control mice. TAK-243 was administered via intravenous injection in B (right) and C . D, hallmark pathways enriched by bulk RNA-seq of Myc-CaP cells with Uba1 depletion (sg Uba1 ) vs. control, with or without IFN-γ stimulation, or Myc-CaP cells treated with or without 50 nmol/L TAK-243 for 18 hours, and stimulated with or without IFN-γ. IFN-γ or IFN-α response pathways are highlighted in red in A – D . E, Surface expression of MHC-I measured by flow cytometry in Myc-CaP cells with Uba1 depletion (sg Uba1 ) or UBA1 inhibition by 18 hours of 50 nmol/L TAK-243 treatment, in the presence or absence of IFN-γ stimulation. Nontargeting sgRNA or DMSO were used as controls, respectively. Data were acquired from biological triplicates. F, Surface expression of MHC-I measured by flow cytometry in GFP-labeled Myc-CaP tumor cells that were Uba1 depleted or inactivated ( n = 4 mice, per group). G, Mass spectrometry measuring protein abundance in Myc-CaP cells treated with 100 nmol/L TAK-243 for 4 hours and subsequently 50 µg/mL of cycloheximide (CHX) for an additional 6 hours. LFC, Log 2 fold change. H, CRISPR knockout screens with sgRNAs targeting genes that were robustly upregulated by TAK-243 in G , in Myc-CaP cells that received TAK-243 and IFN-γ co-treatment (left) or TAK-243 and IFN-β co-treatment (right). I, Immunoblot analysis assessing levels of the indicated proteins in Myc-CaP cells with Uba1 depletion (sg Uba1 ) or 18 hours of 50 nmol/L TAK-243 treatment in the presence of IFN-γ stimulation. Nontargeting sgRNA or DMSO were used as controls, respectively. J, Left: immunoblot analysis assessing JAK1 expression in Myc-CaP cells that received knockout of Jak1 ( Jak1 KO). Cells receiving nontargeting sgRNA were used as control. Right: surface expression of MHC-I measured by flow cytometry in the indicated cells treated with or without 50 nmol/L TAK-243 and stimulated with or without IFN-γ. Data were acquired from technical triplicates, representative of two independent experiments. K, Volumes of tumors derived from Myc-CaP cells established as in J , in mice treated with or without the combination (combo) of anti-PD-1 and TAK-243 ( n = 5 mice, per group). Data in J and K are representative of two independent experiments with two distinct sgRNAs. IFN-γ stimulation was performed at 1 ng/mL for 18 hours. All immunoblot analysis was representative of two independent experiments. Data are presented as mean ± SEM. Statistics were acquired by the two-tailed Student t test in E , F (TAK-243 vs. DMSO), and J , or by two-way ANOVA in F (sg Uba1 vs. control) and K . **, P P

Year:

2025

Depletion of Stub1 upregulates JAK1. A, Top: immunoblot analysis assessing levels of the indicated proteins in Myc-CaP cells that received distinct siRNAs or sgRNAs targeting Stub1 . Nontargeting siRNA or sgRNA was used as control, respectively. Bottom: immunoblot analysis assessing levels of the indicated proteins in the indicated Myc-CaP cells. OE, overexpression. B, Representative images of multiplex immunofluorescence staining for the indicated proteins in UBA1-high and UBA1-low human tumor samples. CK, pan-cytokeratin. Scale bar, 50 µm. C, Schematic showing that UBA1 upregulation in tumor cells facilitates STUB1-mediated proteasomal degradation of a key IFN sensor, JAK1, resulting in low expression of IFN-stimulated genes and thus an immune-cold tumor microenvironment (left). By contrast, inhibition of UBA1 elevates JAK1 and enhances response to IFNs, contributing to the formation of an immune-hot tumor microenvironment (right).

Year:

2025

UBA1 inhibition synergizes with anti–PD-1 therapy to control tumor growth. A, Change of volume over time of subcutaneous tumors derived from B16-F10 cells in C57BL/6 mice treated with the indicated agents ( n = 5–6 mice, per group). α-PD-1: anti–PD-1; Combo: TAK-243 plus α-PD-1. B, Individual growth curves of tumors in mice treated as in A . Last treatment was administered on day 14 after the initial treatment. CR, complete response. C, Survival of mice treated in A . D, Change of volume over time of the indicted tumor models in their syngeneic hosts treated with the indicated agents ( n = 5–10 mice per group). E, Evaluation of drug synergism, using CombPDX ( 44 ), for the combination of TAK-243 and anti–PD-1 in the indicated models, treated as in A and D . A combination index larger than zero was defined as synergistic ( 44 ). *, P P F, Left: change of volume over time of subcutaneous tumors derived from Myc-CaP cells transfected with nontargeting sgRNA (control) or sgRNAs depleting Uba1 (sg Uba1 ) in FVB mice treated with α-PD-1 or the control IgG ( n = 5 mice per group). Right: Evaluation of synergism using CombPDX for the combination of Uba1 -depletion (sg Uba1 ) and anti-PD-1 in the indicated model. G, Flow cytometry measuring the absolute numbers of IFN-γ + CD8 + T cells in the indicated tumors from syngeneic mice treated with the indicated agents. H, Tumor growth over time of Myc-CaP subcutaneous tumors in control, TAK-243–treated, or TAK-243–treated and anti-PD-1–treated (combo) FVB mice, with (α-CD8) or without (IgG) CD8 + T-cell depletion ( n = 5 mice, per group). I, Tumor growth over time of CT26 subcutaneous tumors at naïve or rechallenged stage, in control, TAK-243–treated, anti–PD-1–treated, or TAK-243–treated and anti–PD-1–treated (combo) BALB/c mice. Rechallenge was performed 4 days after removal of the primary tumors by surgery ( n = 6–8 mice, per group). All data are presented as mean ± SEM, except E (mean) and G (box and whisker plots). Statistics were acquired by two-way ANOVA in A , D , F , and H , by log-rank test in C , or by two-tailed Student’s t test in G .

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (14)

Yuping Zhang

Research Assistant Professor

University of Michigan

UNITED STATES
View details

Ulka Vaishampayan

Professor

University of Michigan

UNITED STATES
View details

Y Leo Lei

Associate Professor with Tenure

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Arul M Chinnaiyan

University of Michigan

UNITED STATES
View details

Rahul Mannan

Assistant Research Professor & Director Histology Lab

University of Michigan

UNITED STATES
View details

Vaibhav Sahai

University of Michigan

UNITED STATES
View details

Jiali Yu

Professor

University of Science and Technology of China

CHINA
View details

Ilona Kryczek

University of Michigan

UNITED STATES
View details

Qiang Zhang

Research Assistant Professor

University of Michigan Medical School

UNITED STATES
View details

weiping Zou

University of Michigan

UNITED STATES
View details

Michael Green

Assistant Professor

University of Michigan

UNITED STATES
View details

THEODORE S. LAWRENCE

Chair, Professor

University of Michigan

UNITED STATES
View details

Gabriel Cruz

University of Michigan

UNITED STATES
View details

Daniel R. Wahl

University of Michigan

UNITED STATES
View details